Emerging Agents and Critical Gaps in CNS Data for EGFR-Mutated NSCLC

The discussion addresses emerging second-line options and systematic limitations in CNS endpoint reporting across trials. Emerging agents include OptiTROP-Lung04, which showed encouraging median PFS benefit and clinically significant overall survival benefit, representing an exciting space awaiting a larger readout. HARMONi-A evaluated ivonesimab, an anti-PD-L1/VEGF bispecific antibody, with chemotherapy, showing meaningful overall survival benefit and preliminary signals that patients with baseline brain metastases may derive particular benefit. Izalontamab brengitecan represents another pipeline agent generating early CNS interest.

Dr. Alder and Dr. Nagpal address significant gaps in CNS data across trials: CNS-specific endpoints are frequently underpowered or secondary; much of the emerging data originates from Chinese trial populations, raising questions about generalizability given known differences in disease biology, mutation spectrum, and exposure history; and optimal sequencing remains undefined.

Critically, leptomeningeal disease is rarely reported as a distinct endpoint in large trials, despite being a growing problem as patients with EGFR-mutated NSCLC survive longer. Dr. Nagpal argues for dedicated leptomeningeal cohorts in future trials rather than lumping these patients with parenchymal brain metastasis populations.

The inconsistency between RECIST and RANO brain metastasis criteria across trials further complicates cross-trial interpretation, particularly because SRS achieves approximately 90% local control for lesions under 1.5 cm, making it essentially impossible to attribute intracranial responses to drug versus prior radiation when treated lesions are included without distinction.